Synopsis
Synopsis
0
VMF
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bromide, Butylscopolammonium
2. Bromide, N-butylscopolammonium
3. Buscapine
4. Buscolysin
5. Buscopan
6. Butylscopolamine
7. Butylscopolammonium Bromide
8. Hyoscinbutylbromide
9. Hyoscine N Butylbromide
10. Hyoscine N-butylbromide
11. N Butylscopolammonium Bromide
12. N-butylbromide, Hyoscine
13. N-butylscopolammonium Bromide
14. Scopolaminebutylbromide
15. Scopolan
1. 149-64-4
2. N-butylscopolammonium Bromide
3. Hyoscine Butylbromide
4. Buscopan
5. Scopolan
6. Buscapine
7. Buscolysin
8. Scobutil
9. Sporamin
10. Amisepan
11. Buscapina
12. Butylmin
13. Donopon
14. Joscine
15. Monospan
16. Scobron
17. Scobutyl
18. Sparicon
19. Tirantil
20. Buscol
21. Scobro
22. Buscolamin
23. Butylscopolammonium Bromide
24. Butylscopolamine Bromide
25. Scopolamine Bromobutylate
26. Hyoscine-n-butyl Bromide
27. Buscolysine
28. Stilbron
29. Hyoscine Butyl Bromide
30. N-butylhyoscinium Bromide
31. Butylhyoscine
32. Scopolamine Butobromide
33. N-butylhyoscine Bromide
34. Scoburen
35. Stibron
36. Hyoscin-n-butyl Bromide
37. Scopolamine Butyl Bromide
38. Scopolamine N-butylbromide
39. N-butylscopolamine Bromide
40. Scopolamine N-butyl Bromide
41. N-butylscopolaminium Bromide
42. (-)-n-butylscopolamine Bromide
43. (-)-scopolamine Butylbromide
44. Mls000069755
45. 0gh9jx37c8
46. (-)-scopolamine N-butyl Bromide
47. Smr000058795
48. Dsstox_cid_2718
49. Dsstox_rid_76697
50. Dsstox_gsid_22718
51. Cas-149-64-4
52. Hyoscine Butobromide
53. Hyoscin-n-butylbromid
54. Butylscopolamin
55. Unii-0gh9jx37c8
56. Buskolamin
57. Antipan
58. Buscogast
59. Hyocimax
60. Scopinal
61. Spasmin
62. Hybrocare
63. Butylscopolamine Bromide [jan]
64. Sr-01000759230
65. Hyoscin-n-butylbromid [german]
66. Spasler-p
67. Hyoscin Butobromide
68. (1?,2?,4?,5?,7?)-9-butyl-7-[(2s)-3-hydroxy-1-oxo-2-phenylpropoxy]-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane Bromide
69. Einecs 205-744-1
70. Mfcd00078561
71. Opera_id_556
72. Ncgc00163224-01
73. Scopolamine (butylbromide)
74. Scopolamine N-n-butylbromide
75. Hyoscine-n-butyl Bromide Bp
76. Schembl25291
77. Mls002153372
78. Mls006013629
79. Chembl1256901
80. Dtxsid1022718
81. Chebi:32123
82. Hms2235k20
83. Hms3714i19
84. Hms3884j15
85. Hy-n0340
86. Tox21_112031
87. Hyoscine Butylbromide [mart.]
88. Scopolamine Butylbromide [jan]
89. Akos016009548
90. Akos037515799
91. Hyoscine Butylbromide [who-dd]
92. Tox21_112031_1
93. Ccg-208412
94. Cs-3142
95. Ncgc00186628-02
96. 3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, Bromide, (7(s)-(1alpha,2beta,4beta,5alpha,7beta))-
97. Ac-34139
98. As-78017
99. N-butylscopolammonium Bromide [mi]
100. Smr004705104
101. Hyoscine Butylbromide [ep Monograph]
102. Butylscopolamine Bromide [green Book]
103. F17660
104. A884250
105. J-008603
106. Sr-01000759230-3
107. N-butyl Scopolamine Bromide (n-butyl Hyoscine Bromide)
108. (-)-scopolamine N-butyl Bromide, >=98% (tlc), Powder
109. Hyoscine Butylbromide, British Pharmacopoeia (bp) Reference Standard
110. Hyoscine Butylbromide, European Pharmacopoeia (ep) Reference Standard
111. (1r,2r,4s,5s,7s)-9-butyl-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane Bromide
112. (2r,4s,5s,7s)-9-butyl-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane Bromide
113. [(1s,2s,4r,5r)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2s)-3-hydroxy-2-phenylpropanoate;bromide
114. 1-alpha-h,5-alpha-h-tropanium, 8-butyl-6-beta,7-beta-epoxy-3-alpha-hydroxy-, Bromide, (-)-tropate
115. 3-oxa-9-azoniatricyclo(3.3.1.0 Sup(2,4))nonane, 9-butyl-7-((2s)-3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, Bromide (1:1),(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-
| Molecular Weight | 440.4 g/mol |
|---|---|
| Molecular Formula | C21H30BrNO4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Exact Mass | 439.13582 g/mol |
| Monoisotopic Mass | 439.13582 g/mol |
| Topological Polar Surface Area | 59.1 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
75
PharmaCompass offers a list of Hyoscine Butyl Bromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hyoscine Butyl Bromide manufacturer or Hyoscine Butyl Bromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hyoscine Butyl Bromide manufacturer or Hyoscine Butyl Bromide supplier.
PharmaCompass also assists you with knowing the Hyoscine Butyl Bromide API Price utilized in the formulation of products. Hyoscine Butyl Bromide API Price is not always fixed or binding as the Hyoscine Butyl Bromide Price is obtained through a variety of data sources. The Hyoscine Butyl Bromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Butylhyoscine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Butylhyoscine, including repackagers and relabelers. The FDA regulates Butylhyoscine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Butylhyoscine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Butylhyoscine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Butylhyoscine supplier is an individual or a company that provides Butylhyoscine active pharmaceutical ingredient (API) or Butylhyoscine finished formulations upon request. The Butylhyoscine suppliers may include Butylhyoscine API manufacturers, exporters, distributors and traders.
click here to find a list of Butylhyoscine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Butylhyoscine DMF (Drug Master File) is a document detailing the whole manufacturing process of Butylhyoscine active pharmaceutical ingredient (API) in detail. Different forms of Butylhyoscine DMFs exist exist since differing nations have different regulations, such as Butylhyoscine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Butylhyoscine DMF submitted to regulatory agencies in the US is known as a USDMF. Butylhyoscine USDMF includes data on Butylhyoscine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Butylhyoscine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Butylhyoscine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Butylhyoscine Drug Master File in Japan (Butylhyoscine JDMF) empowers Butylhyoscine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Butylhyoscine JDMF during the approval evaluation for pharmaceutical products. At the time of Butylhyoscine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Butylhyoscine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Butylhyoscine Drug Master File in Korea (Butylhyoscine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Butylhyoscine. The MFDS reviews the Butylhyoscine KDMF as part of the drug registration process and uses the information provided in the Butylhyoscine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Butylhyoscine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Butylhyoscine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Butylhyoscine suppliers with KDMF on PharmaCompass.
A Butylhyoscine CEP of the European Pharmacopoeia monograph is often referred to as a Butylhyoscine Certificate of Suitability (COS). The purpose of a Butylhyoscine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Butylhyoscine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Butylhyoscine to their clients by showing that a Butylhyoscine CEP has been issued for it. The manufacturer submits a Butylhyoscine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Butylhyoscine CEP holder for the record. Additionally, the data presented in the Butylhyoscine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Butylhyoscine DMF.
A Butylhyoscine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Butylhyoscine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Butylhyoscine suppliers with CEP (COS) on PharmaCompass.
A Butylhyoscine written confirmation (Butylhyoscine WC) is an official document issued by a regulatory agency to a Butylhyoscine manufacturer, verifying that the manufacturing facility of a Butylhyoscine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Butylhyoscine APIs or Butylhyoscine finished pharmaceutical products to another nation, regulatory agencies frequently require a Butylhyoscine WC (written confirmation) as part of the regulatory process.
click here to find a list of Butylhyoscine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Butylhyoscine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Butylhyoscine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Butylhyoscine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Butylhyoscine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Butylhyoscine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Butylhyoscine suppliers with NDC on PharmaCompass.
Butylhyoscine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Butylhyoscine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Butylhyoscine GMP manufacturer or Butylhyoscine GMP API supplier for your needs.
A Butylhyoscine CoA (Certificate of Analysis) is a formal document that attests to Butylhyoscine's compliance with Butylhyoscine specifications and serves as a tool for batch-level quality control.
Butylhyoscine CoA mostly includes findings from lab analyses of a specific batch. For each Butylhyoscine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Butylhyoscine may be tested according to a variety of international standards, such as European Pharmacopoeia (Butylhyoscine EP), Butylhyoscine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Butylhyoscine USP).
